We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:0A4J | London | Ordinary Share | ASTRAZENECA ADR REPRESENTING 0.5 ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5,508 | - |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMAZN
RNS Number : 7648X
AstraZeneca PLC
27 April 2023
27 April 2023 17:30 BST
Results of Annual General Meeting held on 27 April 2023
AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 9 - 13 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.
Resolution Votes for % Votes % Votes cast Total Votes of against of in total votes withheld votes votes cast cast cast as a % of issued share capital To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 1 December 2022 1,264,644,490 99.80 2,524,193 0.20 1,267,168,683 81.76 2,068,894 ------------------------ -------------- ------- ------------ ------- -------------- --------- ----------- 2 To confirm dividends 1,254,919,878 98.92 13,679,112 1.08 1,268,598,990 81.85 638,576 ------------------------ -------------- ------- ------------ ------- -------------- --------- ----------- To reappoint PricewaterhouseCoopers 3 LLP as Auditor 1,260,792,714 99.39 7,718,080 0.61 1,268,510,794 81.85 726,500 ------------------------ -------------- ------- ------------ ------- -------------- --------- ----------- To authorise the Directors to agree the remuneration 4 of the Auditor 1,268,225,831 99.98 270,095 0.02 1,268,495,926 81.85 741,641 ------------------------ -------------- ------- ------------ ------- -------------- --------- ----------- To re-elect Michel Demaré as 5a a Director 1,241,496,328 97.88 26,829,809 2.12 1,268,326,137 81.84 911,430 ------------------------ -------------- ------- ------------ ------- -------------- --------- ----------- To re-elect Pascal 5b Soriot as a Director 1,260,336,535 99.37 7,986,485 0.63 1,268,323,020 81.83 914,729 ------------------------ -------------- ------- ------------ ------- -------------- --------- ----------- To re-elect Aradhana 5c Sarin as a Director 1,265,264,711 99.76 3,062,442 0.24 1,268,327,153 81.84 910,131 ------------------------ -------------- ------- ------------ ------- -------------- --------- ----------- To re-elect Philip Broadley as a 5d Director 1,259,273,602 99.29 9,043,851 0.71 1,268,317,453 81.83 920,114 ------------------------ -------------- ------- ------------ ------- -------------- --------- ----------- To re-elect Euan 5e Ashley as a Director 1,268,022,043 99.98 282,266 0.02 1,268,304,309 81.83 924,629 ------------------------ -------------- ------- ------------ ------- -------------- --------- ----------- To re-elect Deborah 5f DiSanzo as a Director 1,267,959,577 99.97 349,778 0.03 1,268,309,355 81.83 926,746 ------------------------ -------------- ------- ------------ ------- -------------- --------- ----------- To re-elect Diana Layfield as a 5g Director 1,268,027,536 99.98 274,653 0.02 1,268,302,189 81.83 935,378 ------------------------ -------------- ------- ------------ ------- -------------- --------- ----------- To re-elect Sheri 5h McCoy as a Director 1,241,492,257 97.88 26,842,094 2.12 1,268,334,351 81.84 903,216 ------------------------ -------------- ------- ------------ ------- -------------- --------- ----------- To re-elect Tony 5i Mok as a Director 1,261,574,735 99.97 322,367 0.03 1,261,897,102 81.42 7,338,922 ------------------------ -------------- ------- ------------ ------- -------------- --------- ----------- To re-elect Nazneen 5j Rahman as a Director 1,266,284,904 99.85 1,870,104 0.15 1,268,155,008 81.82 1,082,559 ------------------------ -------------- ------- ------------ ------- -------------- --------- ----------- To re-elect Andreas 5k Rummelt as a Director 1,268,030,928 99.98 285,793 0.02 1,268,316,721 81.83 920,846 ------------------------ -------------- ------- ------------ ------- -------------- --------- ----------- To re-elect Marcus Wallenberg as 5l a Director 1,026,140,887 80.93 241,825,345 19.07 1,267,966,232 81.81 1,263,367 ------------------------ -------------- ------- ------------ ------- -------------- --------- ----------- To approve the Annual Report on Remuneration for the year ended 6 31 December 2022 1,195,261,107 94.23 73,125,360 5.77 1,268,386,467 81.84 850,827 ------------------------ -------------- ------- ------------ ------- -------------- --------- ----------- To authorise limited 7 political donations 1,228,047,446 97.76 28,189,687 2.24 1,256,237,133 81.06 13,000,783 ------------------------ -------------- ------- ------------ ------- -------------- --------- ----------- To authorise the Directors to allot 8 shares 1,166,174,071 91.95 102,088,563 8.05 1,268,262,634 81.83 966,964 ------------------------ -------------- ------- ------------ ------- -------------- --------- ----------- To authorise the Directors to disapply 9 pre-emption rights 1,193,686,193 94.15 74,121,064 5.85 1,267,807,257 81.80 1,430,310 ------------------------ -------------- ------- ------------ ------- -------------- --------- ----------- To authorise the Directors to further disapply pre-emption rights for acquisitions and specified 10 capital investments 1,153,850,923 91.25 110,689,108 8.75 1,264,540,031 81.59 4,697,303 ------------------------ -------------- ------- ------------ ------- -------------- --------- ----------- To authorise the Company to purchase 11 its own shares 1,254,158,039 98.92 13,730,760 1.08 1,267,888,799 81.81 1,348,767 ------------------------ -------------- ------- ------------ ------- -------------- --------- ----------- To reduce the notice period 12 for general meetings 1,178,311,157 93.41 83,098,807 6.59 1,261,409,964 81.39 7,827,602 ------------------------ -------------- ------- ------------ ------- -------------- --------- ----------- To adopt new Articles of Association 13 of the Company 1,258,637,857 99.26 9,327,063 0.74 1,267,964,920 81.81 1,272,646 ------------------------ -------------- ------- ------------ ------- -------------- --------- -----------
A copy of the resolutions passed at the AGM (other than resolutions concerning ordinary business) has been submitted to the National Storage Mechanism for publication, and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .
Issued capital
As at 25 April 2023, the number of issued shares of the Company was 1,549,856,584 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca .
Contacts
For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGPPUQCCUPWGAM
(END) Dow Jones Newswires
April 27, 2023 12:30 ET (16:30 GMT)
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions